Skip to content

Study · In vitro (cells) · 2008

5 results

Hypoxia-inducible transcription factor (HIF)-1 alpha stabilization by actin-sequestering protein, thymosin beta-4 (TB4) in Hela cervical tumor cells.

Oh JM, Ryoo IJ, Yang Y, Kim HS, Yang KH, Moon EY

Cancer letters12 Feb 2008Cited by 27 (Europe PMC)

PMID18272284 (opens in a new tab)DOI10.1016/j.canlet.2008.01.004 (opens in a new tab)PepBankPUB-18272284
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In HeLa cervical tumor cells, TB4 proteins increased HIF-1 alpha stabilization and transactivation.

    In plain wordsIn cells, thymosin beta‑4 proteins raised the stability and activity of HIF-1 alpha in cervical tumor cells.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseHIF-1 alpha stabilization and transactivation
    Study

    n: not reported in source

    HeLa cervical tumor cells
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    TB4P increased HIF-1 alpha stabilization and transactivation, which is measured by the increase of hypoxia response element (HRE)-luciferase activity and target gene, vascular endothelial growth factor (VEGF) transcription.
  2. 02LabIn vitro (cells)Mechanism

    In HeLa cervical tumor cells, TB4 proteins increased hypoxia response element luciferase activity.

    In plain wordsIn cells, thymosin beta‑4 proteins raised a reporter signal for HIF-1 alpha activity.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseHRE-luciferase activity
    Study

    n: not reported in source

    HeLa cervical tumor cells
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    TB4P increased HIF-1 alpha stabilization and transactivation, which is measured by the increase of hypoxia response element (HRE)-luciferase activity and target gene, vascular endothelial growth factor (VEGF) transcription.
  3. 03LabIn vitro (cells)Mechanism

    In HeLa cervical tumor cells, TB4 proteins increased transcription of the HIF-1 target gene VEGF.

    In plain wordsIn cells, thymosin beta‑4 proteins raised VEGF gene activity in cervical tumor cells.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseVEGF transcription
    Study

    n: not reported in source

    HeLa cervical tumor cells
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    TB4P increased HIF-1 alpha stabilization and transactivation, which is measured by the increase of hypoxia response element (HRE)-luciferase activity and target gene, vascular endothelial growth factor (VEGF) transcription.
  4. 04LabIn vitro (cells)Mechanism

    In HeLa cervical tumor cells, TB4 proteins elevated ERK phosphorylation.

    In plain wordsIn cells, thymosin beta‑4 proteins raised ERK phosphorylation in cervical tumor cells.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseERK phosphorylation
    Study

    n: not reported in source

    HeLa cervical tumor cells
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    TB4P also elevated ERK phosphorylation.

Studies that did not test the peptide alone1

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 05LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism

    In HeLa cervical tumor cells, the ERK inhibitor PD98059 reduced the HIF-1 alpha increase caused by TB4 proteins.

    In plain wordsIn cells, an ERK blocker cut the rise in HIF-1 alpha that thymosin beta‑4 proteins caused.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseHIF-1 alpha level with ERK inhibitor PD98059
    Study

    n: not reported in source

    HeLa cervical tumor cells
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    PD98059, ERK inhibitor reduced HIF-1 alpha increased by TB4P.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.